This review aims to provide a clinical practice-oriented approach to SARS-CoV-2 vaccination in MS in the era of the COVID-19 pandemic.

Acute disseminated encephalomyelitis (ADEM) has been reported after coronavirus disease 2019 (COVID-19). In this review, the authors systematically included worldwide reported cases on this association.

In this study the authors analyzed COVID-19 patients of 127 centers, diagnosed between 01/2020 and 02/2021, and registered at the European multinational LEOSS registry ‘Lean European Open Survey on SARS-Infected Patients’.

In this article the authors detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-α and/or -ω in 13.6% of 3,595 patients with critical COVID-19, including 21% of 374 patients > 80 years, and 6.5% of 522 patients with severe COVID-19.

In this article, the authors provide a snapshot of ongoing vaccine efficacy studies, as well as real-world data on vaccine effectiveness and the impact of virus variants of concern.

The authors of this article hypothesize that convalescent plasma has a higher efficacy, as defined by death within 30 days of transfusion, when the convalescent plasma donor and treated patient were in close geographic proximity.

The authors analyse antibodies and T cells of a recently vaccinated, UK cohort, alongside those recovering from natural infection in early 2020.

The objective of this prospective cohort study was to determine associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with COVID-19 among nursing home residents, nursing home staff, and healthcare workers.

The objective of this test negative design study was to estimate the effectiveness of mRNA COVID-19 vaccines against symptomatic infection and severe outcomes (hospital admission or death).

In this article the authors aimed to quantify the risk of acute myocardial infarction and ischaemic stroke associated with COVID-19 by analysing all COVID-19 cases in Sweden.

Using a retrospective cohort study based on electronic health records primarily in the USA, the absolute risks of cerebral and portal vein thrombosis in the two weeks following a diagnosis of COVID-19 were calculated.

This study aimed to summarize the global research evidence describing the effect of COVID-19 isolation measures on the health of people living with dementia.

The authors of this study report the safety and immunogenicity of heterologous schedules with the ChAd and BNT vaccines.

For this multicentre cohort study, clinicians were asked to submit all cases in which COVID-19 vaccination preceded the onset of cerebral venous thrombosis, regardless of the type of vaccine, interval between vaccine and onset of cerebral venous thrombosis symptoms, or blood test results.

In this study the authors aimed to establish whether inhaled budesonide reduces time to recovery and COVID-19-related hospital admissions or deaths among people at high risk of complications in the community.